Opendata, web and dolomites

SmallDrugRheuma SIGNED

Discovery of Immune Therapeutic Targets and Immunomodulators for the Development of Novel Therapies in Rheumatoid Arthritis.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SmallDrugRheuma project word cloud

Explore the words cloud of the SmallDrugRheuma project. It provides you a very rough idea of what is the project "SmallDrugRheuma" about.

cell    characterizes    boosting    translated    joint    rheumatoid    elucidation    mechanisms    career    cas9    company    integrate    quality    disabling    rnaseq    chronic    candidates    progress    originality    multiple    treatment    inflammation    compounds    proof    patients    repurposing    partnership    counterbalancing    disease    striking    immunotherapy    vivo    potentially    employed    small    action    of    utility    percentage    deformity    therapies    immunotherapeutics    immune    containing    public    interdisciplinary    technologies    cardiovascular    expertise    auto    prevalence    inflammatory    competitiveness    effort    pharmaceutical    umbrella    joints    mechanism    arthritis    environment    cancer    cells    chemoproteomics    altered    cutting    exist    extensive    autoimmune       screening    treat    modulation       pain    library    adulthood    crispr    modulate    molecules    ra    libraries    frequent    productive    approved    diseases    private    ultimately    ex    drugs    prevent    possibilities    therapeutic    tested    edge    immunology    arthropathies    researcher    swelling    chemical    place   

Project "SmallDrugRheuma" data sheet

The following table provides information about the project.

Coordinator
UNIVERSIDAD DE SANTIAGO DE COMPOSTELA 

Organization address
address: COLEXIO DE SAN XEROME PRAZA DO OBRADOIRO S/N
city: SANTIAGO DE COMPOSTELA
postcode: 15782
website: http://www.usc.es

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 170˙121 €
 EC max contribution 170˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-06-29   to  2020-06-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSIDAD DE SANTIAGO DE COMPOSTELA ES (SANTIAGO DE COMPOSTELA) coordinator 170˙121.00

Map

 Project objective

Rheumatoid Arthritis (RA) is an autoimmune chronic disease, characterized by inflammation in multiple joints, ultimately leading to joint deformity, pain and swelling. RA is one of the most frequent inflammatory arthropathies, with a prevalence of 0.3%-1%, striking during the most productive years of adulthood, and is a chronic disabling condition. No therapies exist to prevent RA, and a high percentage of patients do not respond to currently available therapies. Our research aims to integrate expertise on immunology and cutting-edge screening technologies to identify novel immunotherapeutics for RA based on immune modulation mechanisms. The project makes use of an extensive screening effort using a chemical library (60,000 compounds) containing repurposing drugs (drugs already approved for their use for the treatment of other diseases), targeted libraries and lead-like compounds. The aim of the project is to identify novel small molecules capable to modulate the immune response, counterbalancing the altered inflammatory environment that characterizes RA. Elucidation of the mechanism of action of the candidates (cell type, pathway and target) will take place through state-of-the art technologies such as chemoproteomics, RNASeq or CRISPR/Cas9. Ultimately, the most promising candidates will be tested ex vivo in cells from RA patients, providing a proof-of-concept of the therapeutic utility of the identified mechanism. The project is interdisciplinary and will make progress beyond the state of the art, as the identified immunotherapeutics could also be employed to treat other (auto)immune diseases, as well as being potentially translated to immunotherapy of cancer and cardiovascular diseases. The high-quality and originality of this proposal will open up the best career possibilities for the experienced researcher, and will be carried out under the umbrella of a public-private partnership with a pharmaceutical company, boosting European competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMALLDRUGRHEUMA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMALLDRUGRHEUMA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NPsVLCD (2019)

Natural Product-Inspired Therapies for Leishmaniasis and Chagas Disease

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More